High prevalence of the CD14-159CC genotype in patients infected with severe acute respiratory syndrome-associated coronavirus.
Identifieur interne : 001D93 ( PubMed/Checkpoint ); précédent : 001D92; suivant : 001D94High prevalence of the CD14-159CC genotype in patients infected with severe acute respiratory syndrome-associated coronavirus.
Auteurs : Fang F. Yuan [Australie] ; Ingrid Boehm ; Paul K S. Chan ; Katherine Marks ; Julian W. Tang ; David S C. Hui ; Joseph J Y. Sung ; Wayne B. Dyer ; Andrew F. Geczy ; John S. SullivanSource :
- Clinical and vaccine immunology : CVI [ 1556-679X ] ; 2007.
Descripteurs français
- KwdFr :
- Génotype, Hong Kong (épidémiologie), Humains, Immunité innée (génétique), Indice de gravité médicale, Intervalles de confiance, Odds ratio, Polymorphisme génétique, Prédisposition génétique à une maladie, Prévalence, Récepteur de type Toll-2 (métabolisme), Récepteur de type Toll-4 (métabolisme), Syndrome respiratoire aigu sévère (génétique), Syndrome respiratoire aigu sévère (immunologie), Virus du SRAS (immunologie), Études cas-témoins, Évolution de la maladie.
- MESH :
- génétique : Immunité innée, Syndrome respiratoire aigu sévère.
- immunologie : Syndrome respiratoire aigu sévère, Virus du SRAS.
- métabolisme : Récepteur de type Toll-2, Récepteur de type Toll-4.
- épidémiologie : Hong Kong.
- Génotype, Humains, Indice de gravité médicale, Intervalles de confiance, Odds ratio, Polymorphisme génétique, Prédisposition génétique à une maladie, Prévalence, Études cas-témoins, Évolution de la maladie.
English descriptors
- KwdEn :
- Case-Control Studies, Confidence Intervals, Disease Progression, Genetic Predisposition to Disease, Genotype, Hong Kong (epidemiology), Humans, Immunity, Innate (genetics), Lipopolysaccharide Receptors (genetics), Lipopolysaccharide Receptors (immunology), Odds Ratio, Polymorphism, Genetic, Prevalence, SARS Virus (immunology), Severe Acute Respiratory Syndrome (genetics), Severe Acute Respiratory Syndrome (immunology), Severity of Illness Index, Toll-Like Receptor 2 (metabolism), Toll-Like Receptor 4 (metabolism).
- MESH :
- chemical , genetics : Lipopolysaccharide Receptors.
- epidemiology : Hong Kong.
- genetics : Immunity, Innate, Severe Acute Respiratory Syndrome.
- chemical , immunology : Lipopolysaccharide Receptors, SARS Virus, Severe Acute Respiratory Syndrome.
- chemical , metabolism : Toll-Like Receptor 2, Toll-Like Receptor 4.
- Case-Control Studies, Confidence Intervals, Disease Progression, Genetic Predisposition to Disease, Genotype, Humans, Odds Ratio, Polymorphism, Genetic, Prevalence, Severity of Illness Index.
Abstract
To investigate whether genetic factors of innate immunity might influence susceptibility and/or progression in individuals infected with SARS, we evaluated the CD14 gene polymorphism in 198 Hong Kong blood donors and 152 Hong Kong severe acute respiratory syndrome (SARS) patients who were previously genotyped for FcgammaRIIA polymorphisms. The prevalence of the CD14-159CC polymorphism was significantly higher in the patients with severe SARS than in the those with mild SARS or controls (31% versus 15% [mild SARS] or 20% [controls]; mild SARS: P = 0.029; odds ratio, 2.74; 95% confidence interval, 1.15 to 6.57; controls, P = 0.04; odds ratio, 2.41; 95% confidence interval, 1.05 to 5.54), and both CD14-159CC and FcgammaRIIA-RR131 are risk genotypes for severe SARS-CoV infection.
DOI: 10.1128/CVI.00100-07
PubMed: 17913858
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:17913858Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">High prevalence of the CD14-159CC genotype in patients infected with severe acute respiratory syndrome-associated coronavirus.</title><author><name sortKey="Yuan, Fang F" sort="Yuan, Fang F" uniqKey="Yuan F" first="Fang F" last="Yuan">Fang F. Yuan</name><affiliation wicri:level="1"><nlm:affiliation>Cell Biology Laboratory, ARCBS-Endeavour, 153 Clarence Street, Sydney, NSW 2000, Australia. fyuan@arcbs.redcross.org.au</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cell Biology Laboratory, ARCBS-Endeavour, 153 Clarence Street, Sydney, NSW 2000</wicri:regionArea><wicri:noRegion>NSW 2000</wicri:noRegion></affiliation></author><author><name sortKey="Boehm, Ingrid" sort="Boehm, Ingrid" uniqKey="Boehm I" first="Ingrid" last="Boehm">Ingrid Boehm</name></author><author><name sortKey="Chan, Paul K S" sort="Chan, Paul K S" uniqKey="Chan P" first="Paul K S" last="Chan">Paul K S. Chan</name></author><author><name sortKey="Marks, Katherine" sort="Marks, Katherine" uniqKey="Marks K" first="Katherine" last="Marks">Katherine Marks</name></author><author><name sortKey="Tang, Julian W" sort="Tang, Julian W" uniqKey="Tang J" first="Julian W" last="Tang">Julian W. Tang</name></author><author><name sortKey="Hui, David S C" sort="Hui, David S C" uniqKey="Hui D" first="David S C" last="Hui">David S C. Hui</name></author><author><name sortKey="Sung, Joseph J Y" sort="Sung, Joseph J Y" uniqKey="Sung J" first="Joseph J Y" last="Sung">Joseph J Y. Sung</name></author><author><name sortKey="Dyer, Wayne B" sort="Dyer, Wayne B" uniqKey="Dyer W" first="Wayne B" last="Dyer">Wayne B. Dyer</name></author><author><name sortKey="Geczy, Andrew F" sort="Geczy, Andrew F" uniqKey="Geczy A" first="Andrew F" last="Geczy">Andrew F. Geczy</name></author><author><name sortKey="Sullivan, John S" sort="Sullivan, John S" uniqKey="Sullivan J" first="John S" last="Sullivan">John S. Sullivan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17913858</idno><idno type="pmid">17913858</idno><idno type="doi">10.1128/CVI.00100-07</idno><idno type="wicri:Area/PubMed/Corpus">001D12</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001D12</idno><idno type="wicri:Area/PubMed/Curation">001D12</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001D12</idno><idno type="wicri:Area/PubMed/Checkpoint">001D93</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001D93</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">High prevalence of the CD14-159CC genotype in patients infected with severe acute respiratory syndrome-associated coronavirus.</title><author><name sortKey="Yuan, Fang F" sort="Yuan, Fang F" uniqKey="Yuan F" first="Fang F" last="Yuan">Fang F. Yuan</name><affiliation wicri:level="1"><nlm:affiliation>Cell Biology Laboratory, ARCBS-Endeavour, 153 Clarence Street, Sydney, NSW 2000, Australia. fyuan@arcbs.redcross.org.au</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cell Biology Laboratory, ARCBS-Endeavour, 153 Clarence Street, Sydney, NSW 2000</wicri:regionArea><wicri:noRegion>NSW 2000</wicri:noRegion></affiliation></author><author><name sortKey="Boehm, Ingrid" sort="Boehm, Ingrid" uniqKey="Boehm I" first="Ingrid" last="Boehm">Ingrid Boehm</name></author><author><name sortKey="Chan, Paul K S" sort="Chan, Paul K S" uniqKey="Chan P" first="Paul K S" last="Chan">Paul K S. Chan</name></author><author><name sortKey="Marks, Katherine" sort="Marks, Katherine" uniqKey="Marks K" first="Katherine" last="Marks">Katherine Marks</name></author><author><name sortKey="Tang, Julian W" sort="Tang, Julian W" uniqKey="Tang J" first="Julian W" last="Tang">Julian W. Tang</name></author><author><name sortKey="Hui, David S C" sort="Hui, David S C" uniqKey="Hui D" first="David S C" last="Hui">David S C. Hui</name></author><author><name sortKey="Sung, Joseph J Y" sort="Sung, Joseph J Y" uniqKey="Sung J" first="Joseph J Y" last="Sung">Joseph J Y. Sung</name></author><author><name sortKey="Dyer, Wayne B" sort="Dyer, Wayne B" uniqKey="Dyer W" first="Wayne B" last="Dyer">Wayne B. Dyer</name></author><author><name sortKey="Geczy, Andrew F" sort="Geczy, Andrew F" uniqKey="Geczy A" first="Andrew F" last="Geczy">Andrew F. Geczy</name></author><author><name sortKey="Sullivan, John S" sort="Sullivan, John S" uniqKey="Sullivan J" first="John S" last="Sullivan">John S. Sullivan</name></author></analytic><series><title level="j">Clinical and vaccine immunology : CVI</title><idno type="eISSN">1556-679X</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Case-Control Studies</term><term>Confidence Intervals</term><term>Disease Progression</term><term>Genetic Predisposition to Disease</term><term>Genotype</term><term>Hong Kong (epidemiology)</term><term>Humans</term><term>Immunity, Innate (genetics)</term><term>Lipopolysaccharide Receptors (genetics)</term><term>Lipopolysaccharide Receptors (immunology)</term><term>Odds Ratio</term><term>Polymorphism, Genetic</term><term>Prevalence</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (genetics)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severity of Illness Index</term><term>Toll-Like Receptor 2 (metabolism)</term><term>Toll-Like Receptor 4 (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Génotype</term><term>Hong Kong (épidémiologie)</term><term>Humains</term><term>Immunité innée (génétique)</term><term>Indice de gravité médicale</term><term>Intervalles de confiance</term><term>Odds ratio</term><term>Polymorphisme génétique</term><term>Prédisposition génétique à une maladie</term><term>Prévalence</term><term>Récepteur de type Toll-2 (métabolisme)</term><term>Récepteur de type Toll-4 (métabolisme)</term><term>Syndrome respiratoire aigu sévère (génétique)</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Virus du SRAS (immunologie)</term><term>Études cas-témoins</term><term>Évolution de la maladie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Lipopolysaccharide Receptors</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Hong Kong</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Immunity, Innate</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Immunité innée</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Lipopolysaccharide Receptors</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Toll-Like Receptor 2</term><term>Toll-Like Receptor 4</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Récepteur de type Toll-2</term><term>Récepteur de type Toll-4</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Hong Kong</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Case-Control Studies</term><term>Confidence Intervals</term><term>Disease Progression</term><term>Genetic Predisposition to Disease</term><term>Genotype</term><term>Humans</term><term>Odds Ratio</term><term>Polymorphism, Genetic</term><term>Prevalence</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Génotype</term><term>Humains</term><term>Indice de gravité médicale</term><term>Intervalles de confiance</term><term>Odds ratio</term><term>Polymorphisme génétique</term><term>Prédisposition génétique à une maladie</term><term>Prévalence</term><term>Études cas-témoins</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To investigate whether genetic factors of innate immunity might influence susceptibility and/or progression in individuals infected with SARS, we evaluated the CD14 gene polymorphism in 198 Hong Kong blood donors and 152 Hong Kong severe acute respiratory syndrome (SARS) patients who were previously genotyped for FcgammaRIIA polymorphisms. The prevalence of the CD14-159CC polymorphism was significantly higher in the patients with severe SARS than in the those with mild SARS or controls (31% versus 15% [mild SARS] or 20% [controls]; mild SARS: P = 0.029; odds ratio, 2.74; 95% confidence interval, 1.15 to 6.57; controls, P = 0.04; odds ratio, 2.41; 95% confidence interval, 1.05 to 5.54), and both CD14-159CC and FcgammaRIIA-RR131 are risk genotypes for severe SARS-CoV infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17913858</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-679X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>12</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Clinical and vaccine immunology : CVI</Title><ISOAbbreviation>Clin. Vaccine Immunol.</ISOAbbreviation></Journal><ArticleTitle>High prevalence of the CD14-159CC genotype in patients infected with severe acute respiratory syndrome-associated coronavirus.</ArticleTitle><Pagination><MedlinePgn>1644-5</MedlinePgn></Pagination><Abstract><AbstractText>To investigate whether genetic factors of innate immunity might influence susceptibility and/or progression in individuals infected with SARS, we evaluated the CD14 gene polymorphism in 198 Hong Kong blood donors and 152 Hong Kong severe acute respiratory syndrome (SARS) patients who were previously genotyped for FcgammaRIIA polymorphisms. The prevalence of the CD14-159CC polymorphism was significantly higher in the patients with severe SARS than in the those with mild SARS or controls (31% versus 15% [mild SARS] or 20% [controls]; mild SARS: P = 0.029; odds ratio, 2.74; 95% confidence interval, 1.15 to 6.57; controls, P = 0.04; odds ratio, 2.41; 95% confidence interval, 1.05 to 5.54), and both CD14-159CC and FcgammaRIIA-RR131 are risk genotypes for severe SARS-CoV infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Fang F</ForeName><Initials>FF</Initials><AffiliationInfo><Affiliation>Cell Biology Laboratory, ARCBS-Endeavour, 153 Clarence Street, Sydney, NSW 2000, Australia. fyuan@arcbs.redcross.org.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boehm</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Paul K S</ForeName><Initials>PK</Initials></Author><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Julian W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Hui</LastName><ForeName>David S C</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Joseph J Y</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Dyer</LastName><ForeName>Wayne B</ForeName><Initials>WB</Initials></Author><Author ValidYN="Y"><LastName>Geczy</LastName><ForeName>Andrew F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>John S</ForeName><Initials>JS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Vaccine Immunol</MedlineTA><NlmUniqueID>101252125</NlmUniqueID><ISSNLinking>1556-679X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018950">Lipopolysaccharide Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051195">Toll-Like Receptor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="Y">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006723" MajorTopicYN="N">Hong Kong</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018950" MajorTopicYN="N">Lipopolysaccharide Receptors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051195" MajorTopicYN="N">Toll-Like Receptor 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17913858</ArticleId><ArticleId IdType="pii">CVI.00100-07</ArticleId><ArticleId IdType="doi">10.1128/CVI.00100-07</ArticleId><ArticleId IdType="pmc">PMC2168372</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Genet. 2000 Jun;25(2):187-91</Citation><ArticleIdList><ArticleId IdType="pubmed">10835634</ArticleId></ArticleIdList></Reference><Reference><Citation>Biotechniques. 2001 Jul;31(1):22-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11464514</ArticleId></ArticleIdList></Reference><Reference><Citation>FEMS Immunol Med Microbiol. 2001 Jul;31(1):53-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11476982</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Apr;77(8):4588-96</Citation><ArticleIdList><ArticleId IdType="pubmed">12663765</ArticleId></ArticleIdList></Reference><Reference><Citation>Tissue Antigens. 2005 Oct;66(4):291-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16185324</ArticleId></ArticleIdList></Reference><Reference><Citation>Allergy. 2004 May;59(5):520-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15080833</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Diagn Lab Immunol. 2004 May;11(3):625-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15138193</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Cell Mol Biol. 1999 May;20(5):976-83</Citation><ArticleIdList><ArticleId IdType="pubmed">10226067</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Drug Targets Inflamm Allergy. 2005 Apr;4(2):169-75</Citation><ArticleIdList><ArticleId IdType="pubmed">15853738</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Med (Berl). 2003 Jun;81(6):368-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12743710</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Australie</li></country></list><tree><noCountry><name sortKey="Boehm, Ingrid" sort="Boehm, Ingrid" uniqKey="Boehm I" first="Ingrid" last="Boehm">Ingrid Boehm</name><name sortKey="Chan, Paul K S" sort="Chan, Paul K S" uniqKey="Chan P" first="Paul K S" last="Chan">Paul K S. Chan</name><name sortKey="Dyer, Wayne B" sort="Dyer, Wayne B" uniqKey="Dyer W" first="Wayne B" last="Dyer">Wayne B. Dyer</name><name sortKey="Geczy, Andrew F" sort="Geczy, Andrew F" uniqKey="Geczy A" first="Andrew F" last="Geczy">Andrew F. Geczy</name><name sortKey="Hui, David S C" sort="Hui, David S C" uniqKey="Hui D" first="David S C" last="Hui">David S C. Hui</name><name sortKey="Marks, Katherine" sort="Marks, Katherine" uniqKey="Marks K" first="Katherine" last="Marks">Katherine Marks</name><name sortKey="Sullivan, John S" sort="Sullivan, John S" uniqKey="Sullivan J" first="John S" last="Sullivan">John S. Sullivan</name><name sortKey="Sung, Joseph J Y" sort="Sung, Joseph J Y" uniqKey="Sung J" first="Joseph J Y" last="Sung">Joseph J Y. Sung</name><name sortKey="Tang, Julian W" sort="Tang, Julian W" uniqKey="Tang J" first="Julian W" last="Tang">Julian W. Tang</name></noCountry><country name="Australie"><noRegion><name sortKey="Yuan, Fang F" sort="Yuan, Fang F" uniqKey="Yuan F" first="Fang F" last="Yuan">Fang F. Yuan</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001D93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:17913858
|texte= High prevalence of the CD14-159CC genotype in patients infected with severe acute respiratory syndrome-associated coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:17913858" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |